Overview

A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis

Status:
Active, not recruiting

Trial end date:
2022-05-10

Target enrollment:

Participant gender:

Summary

This is a Phase 4, multicenter, single-arm, open-label study to evaluate the impact of apremilast, either in monotherapy or with stable Methotrexate (MTX), on Magnetic resonance imaging (MRI) outcomes in subjects with active PsA with up to 5 years of disease duration (since diagnosis).

Phase:

Phase 4

Details

Lead Sponsor:

Amgen
Celgene

Treatments:

Apremilast
Thalidomide